

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P3121R1

Serial No.

09/964,994

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant


Audrey Goddard et al.

Filing Date

26 Sep 2001

Group

1646



U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
OK	1	4,179,337	18.12.79	Davis et al.			
	2	4,275,149	23.06.81	Litman et al.			
	3	4,301,144	17.11.81	Iwashita et al.			
	4	4,496,689	29.01.85	Mitra, G.			
	5	4,640,835	03.02.87	Shimizu et al.			
	6	4,657,760	14.05.87	Kung et al.			
	7	4,670,417	02.06.87	Iwasaki et al.			
	8	4,676,980	30.06.87	Segal et al.			
	9	4,736,866	12.04.88	Leder et al.			
	10	4,791,192	13.12.88	Nakagawa et al.			
	11	4,816,567	28.03.89	Cabilly et al.			
	12	4,870,009	26.09.89	Evans et al.			
	13	5,206,344	27.04.93	Katre et al.			
	14	5,225,212	06.07.94	Martin et al.			
	15	5,364,934	15.11.94	Drayna et al.			
	16	5,536,637	16.07.96	Jacobs, K.			
	17	5,545,806	13.08.96	Lonberg et al.			
	18	5,545,807	13.08.96	Surani et al.			
	19	5,569,825	29.10.96	Lonberg et al.			
	20	5,625,126	29.04.97	Lonberg et al.			
	21	5,633,425	27.05.97	Lonberg et al.			
	22	5,654,010	05.08.97	Johnson et al.			
	23	5,661,016	26.08.97	Lonberg et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	24	03089		EP (ENGLISH CLAIMS)				
	25	404,097		EPO (ENGLISH ABSTRACT ATTACHED)				
	26	90/13641		PCT				
	27	91/00360		PCT				
	28	92/20373		PCT				
	29	93/08829		PCT				
	30	93/11161		PCT				
	31	96/07399		PCT				
	32	96/27011		PCT				
	33	96/40072		PCT				

Examiner


Elizabeth C. Kemmer

Date Considered

1/9/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P3121R1

Serial No.

09/964,994

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Audrey Goddard et al.

Filing Date

26 Sep 2001

Group

1646

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	No
34	97/03692		PCT				
35	97/33551		PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

36	Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)
37	Altschul, S.F. et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs" <u>Nucleic Acids Research</u> 25:3389-3402 (1997)
38	Anderson, W.F., "Human gene therapy" <u>Science</u> 256(5058):808-813 (May 8, 1992)
39	Beal and Dervan, "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation" <u>Science</u> 251:1360-1363 (1991)
40	BLAST Results A 1 - A 6 (Dayhoff)
41	BLAST Results B 1 - B 4 (GenBank) CONSIDERED; DO NOT PRINT
42	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
43	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
44	Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G ₁ fragments" <u>Science</u> 229:81-83 (July 1985)
45	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)
46	Caron et al., "Engineered humanized dimeric forms of IgG are more effective antibodies" <u>Journal of Experimental Medicine</u> 176(4):1191-1195 (1992)
47	Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1985)
48	Chevray and Nathans, "Protein Interaction Cloning in Yeast: Identification of Mammalian Proteins That React With the Leucine Zipper of Jun" <u>Proc. Natl. Acad. Sci. USA</u> 89:5789-5793 (July 1992)
49	Chien et al., "The Two-Hybrid System: A method to identify and clone genes for proteins that interact with a protein of interest" <u>Proc. Natl. Acad. Sci. USA</u> 88:9578-9582 (1991)
50	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)
51	Cleland., "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems." <u>Vaccine Design: The Subunit and Adjuvant Approach</u> , Powell and Newman, New York:Plenum Press pps. 439-462 (1995)
* 52	Cohen, Jack S. ed. <u>Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression</u> , Boca Raton, FL: CRC Press, Inc. (1989)

Examiner

E. Kemmer

Date Considered


1/9/03

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



Atty Docket No.

P3121R1

Serial No.

09/964,994

Applicant

Audrey Goddard et al.

Filing Date

26 Sep 2001

Group

1646

OTHER DISCLOSURES (Indicate Author, Title, Date, Pertinent Pages, etc.)

53	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)
54	Coligan et al. <u>Current Protocols in Immunology</u> , Chapter 5, 1(2) (1991)
55	Cooney et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro" <u>Science</u> 241:456-459 (July 22, 1988)
* 56	Creighton, Thomas E. <u>Proteins: Structures and Molecular Properties</u> , N.Y.:W.H. Freeman & Co. (1983)
57	David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase." <u>Biochemistry</u> 13(5):1014-1021 (1974)
58	Dzau et al., "Gene therapy for cardiovascular disease" <u>Trends in Biotechnology</u> 11:205-210 (1993)
59	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985)
60	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)
61	Fields and Song, "A novel genetic system to detect protein-protein interactions" <u>Nature</u> 340:245-246 (1989)
62	Fishwild et al., "High-Avidity Human IgG kappa Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice" <u>Nature Biotechnology</u> 14(7):845-851 (Jul 1996)
63	Gruber et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in <i>Escherichia Coli</i> " <u>Journal of Immunology</u> 152:5368-5374 (1994)
64	Holliger et al., "'Diabodies': Small Bivalent and Bispecific Antibody Fragments." <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-48 (Jul 1993)
65	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)
66	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
67	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)
68	Hora et al., "Controlled Release of Interleukin-2 From Biodegradable Microspheres" <u>Bio/Technology</u> 8:755-758 (August 1990)
69	Johnson et al., "A Month-Long Effect From a Single Injection of Microencapsulated Human Growth Hormone" <u>Nature Medicine</u> 2:795-799 (1996)
70	Jones, P.T. et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
71	Klein et al., "Selection for Genes Encoding Secreted Proteins and Receptors" <u>Proc. Natl. Acad. Sci. USA</u> 93(14):7108-7113 (1996)
72	Kohler, G. and Milstein, C., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)

Examiner

E. Kimmern

Date Considered

1/9/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P3121R1

Serial No.

09/964,994

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Audrey Goddard et al.

Filing Date

26 Sep 2001

Group

1646

OTHER DISCLOSURES (Adding Author, Title, Date, Pertinent Pages, etc.)

73	Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" <u>Journal of Immunology</u> 148(5):1547-1553 (1992)
74	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)
75	Lee et al., "Complexes formed by (pyrimidine) _n (purine) _n DNAs on lowering the pH are three-stranded" <u>Nucl. Acids Res.</u> 6:3073-3091 (1979)
76	Lewis, "Controlled release of bioactive agents from lactide/glycolide polymers" <u>Biodegradable Polymers as Drug Delivery Systems</u> , M. Chasin and R Langer, New York:Marcel Dekker pps. 1-41 (1990)
77	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)
78	Lonberg and Huszar., "Human Antibodies From Transgenic Mice." <u>International Reviews of Immunology</u> 13(1):65-93 (1995)
79	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications" <u>Nature</u> 368(6474):856-859 (Apr 28, 1994)
80	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)
81	Marasco et al., "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp 120 single-chain antibody" <u>Proc. Natl. Acad. Sci. USA</u> 90:7889-7893 (1993)
82	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling" <u>Bio/Technology</u> 10:779-783 (1992)
83	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage." <u>J. Mol. Biol.</u> 222:581-597 (1991)
84	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992)
85	Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <u>J. Am. Chem. Soc.</u> 85:2149-2154 (1963)
86	Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (Oct 1983)
87	Mordenti et al., "The Use of Interspecies Scaling in Toxicokinetics" <u>Toxicokinetics and New Drug Development</u> , Yacobi et al., eds., New York:Pergamon Press pps. 42-96 (1989)
88	Morrison, S., "Immunology: Success in specification" <u>Nature</u> 368(6474):812-813 (Apr 28, 1994)
89	Munson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)
90	Neuberger, M., "Generating high-avidity human Mabs in mice" <u>Nature Biotechnology</u> 14(7):826 (Jul 1996)
91	Nielsen et al., "Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites" <u>Protein Engineering</u> 10(1):1-6 (1997)
92	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)

Examiner

E. Kemmer

Date Considered

1/9/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P3121R1

Serial No.

09/964,994

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Audrey Goddard et al.

Filing Date

26 Sep 2001

Group

1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 93 Okano et al., "Myelin Basic Protein Gene and the Function of Antisense RNA in Its Repression in Myelin-Deficient Mutant Mouse" J. of Neurochemistry 56(2):560-567 (1991)
- 94 Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" Protein Eng. 3(6):547-553 (1990)
- 95 Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" Journal of Immunological Methods 40:219-230 (1981)
- 96 Pluckthun, A., "Antibodies from Escherichia coli" The Pharmacology of Monoclonal Antibodies, Rosenberg and Moore, New York:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)
- 97 Presta, L., "Antibody Engineering" Curr. Op. Struct. Biol. 2:593-596 (1992)
- 98 Riechmann, L. et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (Mar 24, 1988)
- 99 Rossi, J.J., "Making ribozymes work in cells" Current Biology 4:469-471 (1994)
- *100 Sambrook et al. Molecular Cloning: A Laboratory Manual, Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
- 101 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" Journal of Experimental Medicine 175:217-225 (Jan 1, 1992)
- 102 Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity" Journal of Immunology 148(9):2918-2922 (1992)
- 103 Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" Journal of Biological Chemistry 266:14163-14166 (1991)
- 104 Stein and Cohen., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review." Cancer Research 48:2659-2668 (May 15, 1988)
- 105 Stevenson et al., "A Chimeric Antibody With Dual Fc Regions (bisFabFc) Prepared by Manipulations at the IgG Hinge" Anti-Cancer Drug Design 3(4):219-230 (1989)
- *106 Stewart et al. Solid-Phase Peptide Synthesis, San Francisco, CA:W.H. Freeman Co. (1969)
- 107 Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" Methods in Enzymology 121:210-228 (1986)
- 108 Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" Cell 51:503-512 (1987)
- 109 Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" Proc. Natl. Acad. Sci. USA 77(9):5201-5205 (September 1980)
- 110 Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" EMBO Journal 10(12):3655-3659 (1991)
- 111 Tutt et al., "Trispecific F(ab')₃ Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells" J. Immunol. 147(1):60-69 (1991)
- 112 van der Krol, Mol and Stuitje., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences." Biotechniques 6(10):958-976 (1998)

Examiner

E. Kemmerer

Date Considered

1/4/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P3121R1

Serial No.

09/964,994

Applicant

Audrey Goddard et al.

Filing Date

26 Sep 2001

Group

1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 113 Verhoeven, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" Science 239:1534-1536 (Mar 25, 1988)
- 114 von Heijne et al., "A New Method for Predicting Signal Sequence Cleavage Sites." Nucl. Acids Res. 14(11):4683-4690 (1986)
- 115 Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells" Proc. Natl. Acad. Sci. 87:3410-3414 (1990)
- 116 Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" Gene 34(2-3):315-323 (1985)
- 117 Wells et al., "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Subtilisin" Philos. Trans. Royal Soc. London Ser. A 317:415-423 (1986)
- 118 Wolff et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice" Cancer Research 53(11):2560-2565 (1993)
- 119 Wu et al., "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system" Journal of Biological Chemistry 262(10):4429-4432 (1987)
- 120 Zamecnik et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA" Proc. Natl. Acad. Sci. 83:4143-4146 (1986)
- 121 Zapata et al., "Engineering linear F(ab')₂ fragments for efficient production in Escherichia coli and enhanced antiproliferative activity" Protein Engineering 8(10):1057-1062 (1995)
- 122 Zola, "Using Monoclonal Antibodies: Soluble Antigens" Monoclonal Antibodies: A Manual of Techniques, CRC Press, Chapter 6, pps. 147-158 (1987)
- 123 Zoller and Smith, "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" Nucl. Acids Res. 10(20):6487-6500 (1982)

Examiner

E. Kemmer

Date Considered

1/9/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.